Logistics of stem cell isolation, preparation and delivery for heart repair: Concerns of clinicians, manufacturers, investors and public health

Regenerative Medicine

Volumn 3, Issue 1, 2008, Pages 83-91

  Salaway, Tarek ^a   Ilic, Dusko ^b  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b StemLifeLine Inc   (United States)

Author keywords

Clinicians; Heart disease; Industry; Investment; Public health; Stem cells

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT STEM CELL; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CARDIOVASCULAR DISEASE; CELL DIFFERENTIATION; CELL ISOLATION; CLINICAL RESEARCH; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; COST BENEFIT ANALYSIS; DRUG MEGADOSE; EMBRYONIC STEM CELL; GOOD MANUFACTURING PRACTICE; HEALTH ECONOMICS; HEALTH INSURANCE; HEART CELL CULTURE; HEART DISEASE; HEART INFARCTION; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMAGING SYSTEM; INTRACORONARY INFUSION; ISCHEMIC HEART DISEASE; MEDICARE; MYOBLAST; NEOPLASM; NONHUMAN; PATENT; PRIORITY JOURNAL; PUBLIC HEALTH; QUALITY CONTROL; REIMBURSEMENT; REVIEW; STEM CELL EXPANSION; STEM CELL TRANSPLANTATION; ARTICLE; CYTOLOGY; FOOD AND DRUG ADMINISTRATION; HEALTH PERSONNEL ATTITUDE; HEART; LABORATORY DIAGNOSIS; PATHOPHYSIOLOGY; STEM CELL; UNITED STATES;

ATTITUDE OF HEALTH PERSONNEL; HEART; HUMANS; PUBLIC HEALTH; QUALITY CONTROL; SPECIMEN HANDLING; STEM CELLS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 38449092778     PISSN: 17460751     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460751.3.1.83     Document Type: Review

References (32)

1. Li L, Baroja ML, Majumdar A et al.: Human embryonic stem cells possess immune-privileged properties. Stem Cells 22(4), 448-456 (2004).
2. Laflamme MA, Gold J, Xu C et al.: Formation of human myocardium in the rat heart from human embryonic stem cells. Am. J. Pathol. 167(3), 663-671 (2005).
3. Laflamme MA, Chen KY, Naumova AV et al.: Cardiomycytes derived from human embryonic stem cells in pro-survival factors enhance function of infracted rat hearts. Nat. Biotechnol. 25(9), 1015-1024 (2007).
4. Chien KR: Making a play at regrowing hearts. Scientist 20(8), 34 (2006).
5. Hecker I, Birla RK: Engineering the heart piece by piece: state of the art in cardiac tissue engineering. Regen. Med. 2(2), 125-144 (2007).
6. Laflamme MA, Murry CE: Regenerating the heart. Nat. Biotechnol. 23(7), 845-856 (2005).
7. Chien KR: Lost and found: cardiac stem cell therapy revisited. J. Clin. Invest. 116(7), 1838-1840 (2006).
8. Rosenzweig A: Cardiac cell therapy - mixed results from mixed cells. N. Engl. J. Med. 355(12), 1274-1277 (2006).
9. Balsam LB, Robbins BC: Haematopoietic stem cells and repair of the ischemic heart. Clin Sci. 109(6), 483-492 (2006).
10. Hofmann M, Wollert KC, Meyer GP et al.: Monitoring of bone marrow cell homing into the infarcted human myocardium. Circulation 111(17), 2198-2202 (2005).
11. Balsam LB, Wagers AJ, Christensen JL, Kofidis T, Weissman IL, Robbins RC: Haematopoietic stem cells adopt mature haematopoietic faces in ischaemic myocardium. Nature 428(6983), 668-673, (2004).
12. Bittner RE, Schofer C, Weipoltshammer K et al.: Recruitment of bone-marrow-derived cells by skeletal and cardiac muscle in adult dystrophic mdx mice. Anat. Embryol. 199(5), 391-396, (1999).
13. Jackson, KA, Majka SM, Wang H et al.: Regeneration of ischemic cardiac muscle and vascular endothelium by adult stem cells. J. Clin. Invest. 107(11), 1395-1402 (2001).
14. Kajstura J, Rota M, Whang P et al.: Bone marrow cells differentiate in cardiac cell lineages after infarction independently of cell fusion. Circ. Res. 96(1), 127-137 (2005).
15. Kocher AA, Schuster MD, Szaboks MJ et al.: Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat. Med. 7(4), 430-436 (2001).
16. Murry CE, Soonpaa MH, Reinecke H et al.: Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts. Nature 428(6983), 664-668 (2004).
17. Nygren JM, Jovinge S, Breithach M et al.: Bone marrow-derived hematopoietic cells generate cardiomyocytes at a low frequency through cell fusion, but not transdifferentiation. Nat. Med. 10(5), 494-501 (2004).
18. Orlic D, Kajstura J, Chimenti S et al.: Bone marrow cells regenerate infarcted myocardium. Nature 410(6829), 701-705 (2001).
19. Orlic D, Kajstura J, Chimenti S et a.: Mobilized bone marrow cells repair the infarcted heart improving function and survival. Proc. Natl Acad. Sci. USA 98(18), 10344-10349, (2001).
20. Assmus B, Schachinger V, Teupe C et al.: Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE-AMI). Circulation 106(24), 3009-3017 (2002).
21. Perin EC, Dohmann HF, Borojevic R et al.: Transendocardial, autologous bone marrow cell transplantation for severe, chronic ischemic heart failure. Circulation 107(18), 2294-2302, (2003).
22. Stamm C, Westphal B, Kleine HD et al.: Autologous bone-marrow stem-cell transplantation for myocardial regeneration. Lancet 361(9351), 45-46 (2003).
23. Strauer BE, Brehm M, Zeus T et al.: Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans. Circulation 106(15), 1913-1918 (2002).
24. Tse HF, Kwong YI, Chan JK, Lo G, Ho CL, Lau CP: Angiogenesis in ischaemic myocardium by intramyocardial autologous bone marrow mononuclear cell implantation. Lancet 361(9351), 47-49 (2003).
25. Bittira B, Shum-Tim D, Al-Khaldi A, Chiu RC: Mobilization and homing of bone marrow stromal cells in myocardial infarction. Eur. J. Cardiothorac. Surg. 24(3), 393-398, (2003).
26. Ma J, Ge J, Zhang S et al.: Time course of myocardial stromal cell-derived factor I expression and beneficial effects of intravenously administered bone marrow stem cells in rats with experimental myocardial infarction. Basic Res. Cardiol. 100(3), 217-223 (2005).
27. Shake JG, Gruber PJ, Baumgartner WA et al.: Mesenchymal stem cell unplantation in a swine myocardial infarct model: engraftment and functional effects. Ann. Thorac. Surg. 73(6), 1919-1926 (2002).
28. Toma C, Pittenger MF, Cahill KS, Byrne BJ, Kessler PD: Human mesenchymal stem cells diferentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation 105(1), 93-98 (2002).
29. Raikwar SP, Mueller T Zavazara N: Strategies for developing therapeutic application of human embryonic stem cells. Physiology 21(1), 19-28 (2006).
30. Swijnenburg RJ, van der Bogt KE Sheikh AY, Cao F, Wu JC: Clinical hurdles for the transplantation of audiomyocytes derived from human embryonic stem cells: role of molecular imaging. Curr. Opin. Biotechnol. 18(1), 38-45 (2007).
31. Steinberg EP, Tunis S, Shapiro D: Insurance coverage for experimental technologies. Health Aff. 14(4), 143-158 (1995).
32. Dai W, Field LJ, Rubiart M et al.: Survival and maturation of human embryonic stem cell-derived cardiomyocytes in rat hearts. J. Mol. Cell. Cardiol. 43(4), 504-516 (2007).